Skip to search formSkip to main contentSkip to account menu

ecallantide

Known as: DX-88 cpd, EPI-KAL-2 
National Institutes of Health

Related topics

Related topics

4 relations
1 ML ecallantide 10 MG/ML Injection1 ML ecallantide 10 MG/ML Injection [Kalbitor]

Narrower (1)

Kalbitor

Broader (1)

Peptides

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Non-Surgical Management of Colo-Colonic Intussusception in Patients with Hereditary Angioedema
Patient: Female, 17 Final Diagnosis: Colo-colonic intussusception Symptoms: Abdominal pain Medication: — Clinical Procedure… 
2018
2018
First preventive mAb for hereditary angioedema
The US Food and Drug Administration has approved the first monoclonal antibody (mAb) to prevent hereditary angioedema (HEA… 
2016
2016
Novel usage of fresh frozen plasma in hereditary angioedema.
Hereditary angioedema (HAE) is a rare and potentially life threatening autosomal dominant disease characterized by recurrent… 
2016
2016
Shire bites deeper into rare disease space
Dublin-based Shire has agreed to buy Dyax, a company with a rare disease treatment that bolsters its current portfolio in… 
2015
2015
Fresh Frozen Plasma in Hereditary Angioedema Crisis: to Give or Not to Give?
Objectives: Fresh frozen plasma (FFP) has been used in angioedema crises, however there is a risk of aggravating the symptoms as… 
2010
2010
Ecallantide (Kalbitor): A plasma kallikrein inhibitor approved for the treatment of acute attacks of hereditary angioedema
New molecular entity: Ecallantide (Kalbitor) was approved in December 2009, to treat hereditary angioedema (HAE). 
Review
2010
Review
2010
Drug Evaluation Overview of ecallantide in the treatment of hereditary angioedema types I and II
Hereditary angioedema (HAE) is a rare, debilitat‐ ing and potentially fatal disease characterized by unpredictable, acute… 
2010
2010
Introduction: New Perspectives in Hereditary Angioedema (HAE): Molecular Mechanisms & Therapeutic Choices: A CME Symposium Presented at the 2009 World Allergy Congress, Buenos Aires, Argentina…
Hereditary angioedema (HAE), an autosomal dominant disorder that occurs in approximately 1 in 50,000 people, is characterized by… 
Review
2009
Review
2009
FDA Pipeline preview, March 2009 (cetuximab, prasugrel, risperidone, iclaprim, lasofoxifene, ecallantide, laquinimod, C1 inhibitor, SGN-35, omacetaxine)
Recent FDA action (through March 2009) related to cetuximab, prasugrel, risperidone, iclaprim, lasofoxifene, ecallantide… 
2006
2006
Gateways to clinical trials.
Gateways to Clinical Trials are a guide to the most recent clinical trials in current literature and congresses. The data in the… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)